journal article·2018-11-05Open access

A developed antibody–drug conjugate rituximab-vcMMAE shows a potent cytotoxic activity against CD20-positive cell line

Meghdad Abdollahpour-Alitappeh, Seyed Masoud Hashemi Karouei, Majid Lotfinia, Amir Amanzadeh, Mahdi Habibi-Anbouhi

Abstract

Rituximab is a chimeric monoclonal antibody directed against B-lymphocyte specific antigen CD20, which is used for the treatment of B-cell malignancies. However, the effectiveness of rituximab is limited partly due to treatment resistance. The aim of this study was to develop rituximab-based antibody drug conjugate (ADC) to enhance rituximab activity. In this study, monomethyl auristatin E (MMAE) was covalently conjugated to dithiothreitol -reduced rituximab via a valine-citrulline peptide linker (rituximab-vcMMAE). The conjugates were then characterized by using nonreducing sodium dodecyl sulfate-polyacrylamide electrophoresis (SDS-PAGE) and cell-based enzyme-linked immunosorbent assay (ELISA). The cytotoxic activity of the ADC was evaluated against Raji (human B-cell lymphoma; CD20-positive) and MOLT-4 (T lymphoblast; acute lymphoblastic leukemia; CD20-negative) cell lines. In addition, the colony formation assay was used to identify the propagation ability of ADC-treated cells in vitro. Results from nonreducing SDS-PAGE revealed various species of rituximab-MC-Val-Cit-PABC-MMAE (rituximab-vcMMAE), as compared with unconjugated rituximab. The binding capacity of rituximab-vcMMAE to the CD20-positive cell was similar to that of the parental rituximab. Most importantly, our results revealed that rituximab-vcMMAE was highly potent against the CD20-positive cell line, but not against the CD20-negative cell. At the same time, rituximab-vcMMAE was able to inhibit colony formation in CD20-positive cells. These data indicate that rituximab-vcMMAE may be a highly effective and selective therapy for the treatment of B-cell lymphoma.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: HER2/EGFR in Cancer Research · Monoclonal and Polyclonal Antibodies Research · CAR-T cell therapy research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran;

National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran;

Department of Biology, Babol Branch Islamic Azad University, Babol, Iran;

Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Funding

Pasteur Institute of Iran

References (39)

Show source-provided references
1. 10.2174/138920100337905910.2174/1389201003379059 ↗
2. 10.3322/caac.2133210.3322/caac.21332 ↗
3. Dotan E · P T · 2010 · 35 · 148
4. 10.1056/NEJMra070887510.1056/NEJMra0708875 ↗
5. 10.1200/JCO.1998.16.8.278010.1200/JCO.1998.16.8.2780 ↗
6. 10.18632/oncotarget.420610.18632/oncotarget.4206 ↗
7. 10.1016/j.jddst.2015.05.01210.1016/j.jddst.2015.05.012 ↗
8. 10.1016/j.tibtech.2017.03.00110.1016/j.tibtech.2017.03.001 ↗
9. 10.1038/nrd.2016.26810.1038/nrd.2016.268 ↗
10. 10.4062/biomolther.2015.11610.4062/biomolther.2015.116 ↗
11. 10.3390/toxins307084810.3390/toxins3070848 ↗
12. 10.1038/nrd400910.1038/nrd4009 ↗
13. 10.4161/mabs.2169710.4161/mabs.21697 ↗
14. 10.4161/mabs.3.4.1661210.4161/mabs.3.4.16612 ↗
15. 10.1016/j.ejps.2017.02.03410.1016/j.ejps.2017.02.034 ↗
16. 10.18869/acadpub.ibj.21.4.27010.18869/acadpub.ibj.21.4.270 ↗
17. Abdollahpour-Alitappeh M · J Herbmed Pharmacol · 2017 · 6 · 153
18. 10.3233/HAB-17031510.3233/HAB-170315 ↗
19. 10.1016/0006-2952(90)90613-P10.1016/0006-2952(90)90613-P ↗
20. 10.1038/nbt.228910.1038/nbt.2289 ↗
21. 10.1038/nbt83210.1038/nbt832 ↗
22. 10.1021/acs.bioconjchem.6b0005510.1021/acs.bioconjchem.6b00055 ↗
23. 10.1007/s11095-015-1657-710.1007/s11095-015-1657-7 ↗
24. 10.1021/mp500762u10.1021/mp500762u ↗
25. 10.4161/mabs.2677310.4161/mabs.26773 ↗
26. 10.1038/nbt.148010.1038/nbt.1480 ↗
27. 10.1016/j.canlet.2011.03.00210.1016/j.canlet.2011.03.002 ↗
28. 10.1080/15384047.2016.113924810.1080/15384047.2016.1139248 ↗
29. 10.1021/bc050201y10.1021/bc050201y ↗
30. 10.1182/blood-2003-01-003910.1182/blood-2003-01-0039 ↗
31. 10.1158/1078-0432.CCR-04-078910.1158/1078-0432.CCR-04-0789 ↗
32. 10.1371/journal.pone.008386510.1371/journal.pone.0083865 ↗
33. 10.1158/1078-0432.CCR-04-102810.1158/1078-0432.CCR-04-1028 ↗
34. 10.2165/00003495-200363080-0000510.2165/00003495-200363080-00005 ↗
35. 10.1007/978-3-7091-6551-5_110.1007/978-3-7091-6551-5_1 ↗
36. 10.1182/blood-2008-09-17914310.1182/blood-2008-09-179143 ↗
37. 10.1182/blood-2009-02-20550010.1182/blood-2009-02-205500 ↗
38. 10.1007/s00262-016-1873-y10.1007/s00262-016-1873-y ↗
39. 10.1002/cyto.a.2227310.1002/cyto.a.22273 ↗